Hyperfine Q2 2026 earnings: Revenue rises 45% as operating loss narrows

Hyperfine (Nasdaq: HYPR) reported Q2 2026 revenue of $3.904 million, up 44.8% from $2.696 million, while diluted net loss per share was $0.09 versus $0.12 a year earlier. Commercial Swoop system sales increased to 12 from eight and gross margin expanded, helping narrow the operating loss, but interest expense and a warrant-liability valuation loss kept the net loss essentially flat at $9.298 million.

Core earnings data

Revenue growth was concentrated in device sales, while service revenue also increased. Gross profit grew slightly faster than revenue, lifting gross margin by 1.4 percentage points, and lower operating expenses contributed to a narrower operating loss.

The improvement did not extend to absolute net income because unfavorable non-operating items offset the operating progress.

Business and product performance

Device revenue supplied most of the quarterly dollar growth, supported by a 50% increase in commercial Swoop systems sold. Service revenue also grew, but at a slower rate than device sales.

Hyperfine also received CE Marking and UKCA approval for its next-generation Swoop system and latest Optive AI software, followed by the European launch and initial system sales. Management reported record U.S. scan volume across hospital and office settings, although the company did not quantify scan volumes or disclose a geographic revenue breakdown.

Operating leverage improved, but financing items shaped the bottom line

Total operating expenses declined to $10.449 million from $10.923 million. Research and development spending fell 14.9% to $3.865 million, more than offsetting modest increases in general and administrative expenses and sales and marketing expenses. Combined with higher gross profit, this reduced the operating loss by $1.126 million.

Below the operating line, Hyperfine recorded $0.533 million of interest expense, compared with none a year earlier. It also recognized a $0.571 million loss from the change in fair value of warrant liabilities, versus a $0.046 million gain in Q2 2025. The approximately $1.15 million combined year-over-year deterioration in these two items largely offset the improvement in operating results.

The lower per-share loss also needs context. Weighted-average diluted shares increased to 99.8 million from 78.1 million, while the absolute net loss was almost unchanged. The improvement from a $0.12 to a $0.09 loss per share therefore reflected the larger share count rather than lower net losses.

Cash flow and balance sheet

Cash-flow figures were reported for the six months ended June 30 rather than for Q2 alone. First-half operating cash use improved to $16.276 million from $17.159 million, while purchases of property and equipment declined to $0.272 million from $0.992 million.

Cash and cash equivalents rose to $43.458 million at June 30, 2026, from $35.085 million at the end of 2025. The increase primarily reflected $25.270 million of first-half financing inflows, including $13.641 million of net debt proceeds and $11.375 million from the at-the-market equity program.

The stronger cash balance therefore came with additional financing obligations and dilution. Long-term debt reached $13.235 million, compared with none at year-end, while outstanding Class A shares increased to approximately 91.0 million from 82.2 million.

2026 guidance

Hyperfine reaffirmed rather than raised its full-year outlook. The company continues to target substantial revenue growth while expecting a more moderate reduction in cash burn.

Hyperfine defines cash burn as the change in cash and cash equivalents less net financing proceeds.

Recent insider transactions

The supplied six-month insider summary shows 1.41 million shares purchased across three transactions and 61,291 shares sold across five transactions, resulting in net purchases of 1,348,709 shares. However, the purchase transactions are not itemized in the supplied latest-ten list, so the identities, prices and dates associated with those purchases cannot be determined from the available information.

The reported transactions establish only the timing and size of the sales and grants; they do not establish the insiders’ views about Hyperfine’s outlook.

Risks investors should watch

• Second-half execution: First-half revenue was $7.807 million. Reaching the reaffirmed $20 million to $22 million full-year range requires second-half revenue to exceed the first-half level.
• Continued cash consumption: Hyperfine remains unprofitable and expects full-year cash burn of $26 million to $28 million, despite the projected year-over-year reduction.
• Financing and dilution: The higher cash balance primarily resulted from debt and equity financing. Long-term debt and the Class A share count both increased during the first half.
• Non-operating volatility: Interest expense and warrant-liability remeasurement offset Q2 operating improvement and could continue to affect reported net results.
• International commercialization: European and UK approvals expand the addressable market, but the company disclosed only initial European sales and did not quantify the region’s revenue contribution.

Summary

Hyperfine’s Q2 revenue growth was supported by higher Swoop system sales, while gross-margin expansion and lower R&D spending narrowed the operating loss. Absolute net loss remained nearly unchanged because financing-related and warrant-liability items offset that progress, and the improved loss per share was influenced by a larger share count. The main next steps are converting product adoption into enough second-half revenue to meet guidance while controlling cash burn and reliance on external financing.